We have recently reported that primitive human hematopoietic progenitors, capable of initiating long-term bone marrow cultures, termed LTC-IC, are maintained when cocultured with stroma but separated from the stromal layer by a 0.4 m microporous membrane in a """"""""stroma-non-contact"""""""" culture. Preliminary studies indicate that cytokines together with proteoglycans released by stromal cells are responsible for the LTC-IC maintenance capacity of """"""""stroma-non-contact"""""""" cultures. In additional studies we demonstrate a 5-fold increase in LTC-IC number (5 fold expansion) when cultured for 2 weeks in """"""""stroma-non-contact"""""""" cultures supplemented with IL3 and the presumed growth inhibitory cytokine MIP-1alpha, suggesting LTC-IC proliferation (self-renewal). However, the number of LTC-IC present after 5-8 weeks in """"""""stroma-non-contact"""""""" cultures without (40%) or with MIP- 1alpha+IL3 (100%) is lower than or equal to that in the starting population (40-100% maintenance) suggesting that some LTC-IC may not persist or be conserved over time. These studies led us to hypothesize that long-term expansion of LTC-IC in ex vivo cultures will require conditions that induce (A) increased proliferation (LTC-IC undergoing self-renewing cell divisions) and (B) increased conservation of LTC-IC (persistence of LTC-IC over time). We propose a series of studies to identify additional known growth factors and to characterize further diffusible, large molecular weight stroma-derived factors which induce proliferation and conservation of human hematopoietic stem cells. In SA1, we will develop a single cell deposition assay which can evaluate the fate of individual LTC-IC, i.e. is a single LTC-IC conserved? and did a single LTC-IC proliferate? This assay system will then be used to examine the effect of altered culture condiitons as proposed in SA2 and SA3 on the proliferation and conservation of LTC-IC. In addition, we will develop a more rapid screening assay for LTC-IC proliferation using PKH-26 fluorescence labeling of progenitor populations. In SA2, we propose to examine the effect of presumed growth inhibitory cytokines combined with known growth promoting cytokines on the proliferation and conservation of LTC-IC. Cytokines, such as PF4, IL7 and b-FGF, which interact with primitive progenitors, are present at very low concentrations in stromal cultures and can bind to proteoglycans, will be included. Since preliminary studies indicate that proteoglycans produced by stromal feeders are imperative for LTC-IC maintenance, experiments in SA3 will characterize diffusible proteoglycans present in stroma conditioned media required for LTC-IC proliferation/conservation. Once the nature of the glycosaminoglycan side chains and core protein have been identified, synthetic proteoglycans will be constructed and tested for their LTC-IC proliferation/conservation capacity. Finally, in SA4, we propose to demonstrate that multilineage, long-term repopulating, hematopoietic stem cells have expanded in the presence of the cytokines identified in SA2 and proteoglycans identified in SA2 and proteoglycans identified in SA3 by transplanting retrovirally marked progenitors recovered from ex vivo cultures into preimmune lambs. These efforts provide the foundation for additional studies proposed in Project 2 exploring the lymphoid differentiation capacity of hematopoietic stem cells and for clinical trials employing expanded progenitor populations in transplant therapy for malignant diseases as described in Projects 3-5.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA065493-05
Application #
6103005
Study Section
Project Start
1999-07-06
Project End
2000-05-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
5
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Minnesota Twin Cities
Department
Type
DUNS #
168559177
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Sarhan, Dhifaf; Hippen, Keli L; Lemire, Amanda et al. (2018) Adaptive NK Cells Resist Regulatory T-cell Suppression Driven by IL37. Cancer Immunol Res 6:766-775
Williams, Robin L; Cooley, Sarah; Bachanova, Veronika et al. (2018) Recipient T Cell Exhaustion and Successful Adoptive Transfer of Haploidentical Natural Killer Cells. Biol Blood Marrow Transplant 24:618-622
Don Yun, Hyun; Felices, Martin; Vallera, Daniel A et al. (2018) Trispecific killer engager CD16xIL15xCD33 potently induces NK cell activation and cytotoxicity against neoplastic mast cells. Blood Adv 2:1580-1584
Hippen, Keli L; Loschi, Michael; Nicholls, Jemma et al. (2018) Effects of MicroRNA on Regulatory T Cells and Implications for Adoptive Cellular Therapy to Ameliorate Graft-versus-Host Disease. Front Immunol 9:57
Pennell, Christopher A; Barnum, Jessie L; McDonald-Hyman, Cameron S et al. (2018) Human CD19-Targeted Mouse T Cells Induce B Cell Aplasia and Toxicity in Human CD19 Transgenic Mice. Mol Ther 26:1423-1434
Williams, Shelly M; Sumstad, Darin; Kadidlo, Diane et al. (2018) Clinical-scale production of cGMP compliant CD3/CD19 cell-depleted NK cells in the evolution of NK cell immunotherapy at a single institution. Transfusion 58:1458-1467
Mathew, Nimitha R; Baumgartner, Francis; Braun, Lukas et al. (2018) Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nat Med 24:282-291
Romee, Rizwan; Cooley, Sarah; Berrien-Elliott, Melissa M et al. (2018) First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation. Blood 131:2515-2527
Stefanski, Heather E; Jonart, Leslie; Goren, Emily et al. (2018) A novel approach to improve immune effector responses post transplant by restoration of CCL21 expression. PLoS One 13:e0193461
Owen, David L; Mahmud, Shawn A; Vang, Kieng B et al. (2018) Identification of Cellular Sources of IL-2 Needed for Regulatory T Cell Development and Homeostasis. J Immunol 200:3926-3933

Showing the most recent 10 out of 395 publications